4-AMINO-2-FLUORO-N-METHYLBENZAMIDE For Making Enzalutamide CAS Number 915087-25-1

Basic Info

Model No.: 915087-25-1

Additional Info

Packaging: AS REQUIRED

Productivity: KGS

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: TRUE MANUFACTURER

Product Description

Enzalutamide intermediate 5 has the full name of  4-AMINO-2-FLUORO-N-METHYLBENZAMIDE CAS number 915087-25-1, it has variety of synthesis method ,here we simply introduce the advantages and disadvantages of various methods. The first: use nitrotoluene derivatives as raw materials by oxidation, acid chloride solution to get the target compound. The biggest drawback of this route is the low yield, even with the most optimistic way to calculate the total yield will not exceed 50%. Followed by the reagent used in production process has big toxicity, will cause greater harm to workers and the environment. The second:use bromobenzofluorobenzoic acid as a raw material through three steps to get the target compound, this route using reagents such as methyl iodide and other methylation reagents, which has big pollution and will bright a lot of hidden danger to production safety. From the current patent report, E There is almost no reference to the experience and ideas of Enzalutamide intermediate 5 CAS 915087-25-1 synthesis method, companies need to spend their time to explore.

Thera. Category: Treatment of advanced prostate cancer

Cas No.:  915087-25-1

Synonym:  N-Methyl-4-amino-2-fluoro-benzamide;4-amino-2-fluoro-N-menthylbenzamide

Molecular Formula:C8H9FN2O

Molecular Weight: 168.17

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request

Usage:  Enzalutamide (brand name Xtandi) is a nonsteroidal antiandrogen (NSAA) which is used for the treatment of metastatic, castration-resistant prostate cancer (CRPC).[3] An up to 89% decrease in serum prostate specific antigen (PSA) levels have been reported after a month of taking the drug.[4] Research suggests that enzalutamide may also be effective in the treatment of certain types of breast cancer